By Rupa Palanki On September 20, the Federal Trade Commission (FTC) filed a landmark lawsuit against the three largest prescription drug benefit managers (PBMs) — Caremark Rx, Express Scripts, and OptumRx — and their affiliated group purchasing organizations. The FTC alleges that these entities engaged in “anticompetitive and unfair rebating practices,” artificially increasing insulin drug…
The privatization of next-generation medical technologies, especially in regenerative and precision medicine, further muddies the data-protection waters.
What are the risks of using generative AI systems like ChatGPT in medical practice, and who is ultimately held responsible for patient harm?
The regulatory landscape of health-related products contains loopholes that allow false or misleading claims to proliferate.
In January, the FTC released a draft rule that would ban non-compete clauses. This may promote competition and innovation in biotechnology.
In a post-Dobbs world, more women will find the technologies they rely on for their health turned against them as tools of surveillance.
Advertisers are trying to market to us while we dream — a troubling and potentially illegal new reality.
Massive and misleading promises are an unfortunate reality for many fitness products. But regulators can promote accountability.
The Biden/Harris administration appears uniquely poised to implement a comprehensive initiative to address health care consolidation.
By Kate Greenwood [Cross-posted at Health Reform Watch] Earlier this week, the Food and Drug Administration announced that it was reopening the comment periods for the two draft guidances on the use of social media to promote prescription drugs and medical devices that it released in June: Internet/Social Media Platforms with Character Space Limitations: Presenting Risk and…
